Evolus Inc: Down on Q4 revenue miss, bigger net loss

Medy-Tox

25/03/2021 10:55

** Shares of medical aesthetics co  EOLS.O  down 12.4% at
$14.45 premarket
    ** Co posts Q4 revenue of $20.6 mln, below analysts'
estimates of $21 mln - Refinitiv IBES
    ** Q4 net loss widens to $3.28 per share, compared with 47
cents per share a year earlier
    ** EOLS says revenue was impacted by selling under a bond
required by the International Trade Commission (ITC) beginning
mid-December 2020, which resulted minimal net revenue in the
last two weeks of Q4  urn:newsml:reuters.com:*:nGNX6k4r5H
    ** Expects Allergan/Medytox settlement agreements announced
in February and the settlement agreement with Daewoong
Pharmaceutical announced in March to temporarily impact its
gross margin profile negatively through September 2022
    ** Co on Tuesday announced several deals with strategic
partner Daewoong Pharmaceutical to strengthen its balance sheet
 urn:newsml:reuters.com:*:nGNXbd0y7H
    ** Last month, EOLS, AbbVie  ABBV.N  and Medytox agreed to
resolve all outstanding litigation, including the U.S. ITC case
regarding the sale of EOLS's Botox-rival, Jeuveau  urn:newsml:reuters.com:*:nL4N2KP3E2
    ** EOLS expects 2021 full-year gross margin to be between
50% and 55%
    ** Up to last close, stock had nearly tripled in value this
year

 (Reporting by Rithika Krishna in Bengaluru)
 ((Rithika.Krishna@thomsonreuters.com;))